Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to curb impulse control in Parkinson's

NCT ID NCT06237868

Symptom relief Sponsor: West Virginia University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a non-invasive brain stimulation technique called rTMS can reduce impulse control disorders in people with Parkinson's disease who are on dopamine therapy. Twenty participants will receive both real and sham stimulation in random order, then complete tasks measuring impulsivity and learning. The goal is to see if rTMS over the prefrontal cortex can help patients make better choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could point toward a non-drug way to help Parkinson's patients manage impulse control issues like compulsive gambling or shopping.
What could go wrong
This is a very small, early study with only 20 people. It tests just one or two sessions, so any benefits may be short-lived or not work at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinician-confirmed diagnosis of PD * Ability to provide informed consent, written and verbal * Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome * A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower * A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher * On dopamine-replacement therapy Exclusion Criteria: * History of seizures or epilepsy * History of brain lesions (such as multiple sclerosis, tumor) reported * History of vascular issues in the brain, such as stroke * History of a moderate to severe traumatic brain injury * Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher). * Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005) * Having had TMS done in the recent past (within a year) * Pregnancy assessed in female patients * Intracranial metallic objects (except for dental fillings) * Current use of substances or medications known to significantly reduce seizure threshold.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Impulse control disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Disruptive, Impulse Control, and Conduct Disorders impulse control disorder Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Impulse control disorder Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West Virginia University Hospitals

    RECRUITING

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.